Communiqués Sonnet Biotherapeutics

Actions

SONN

US83548R4020

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/12/2025			Varia. 5j.	Varia. 1 janv.
1,260 ^USD	-59,35 %		-.--%	-

16/12	Sonnet BioTherapeutics Holdings, Inc. publie ses résultats financiers pour l'exercice clos le 30 septembre 2025	CI
02/12	Forte baisse à la mi-journée pour Sonnet BioTherapeutics, Janux Therapeutics et Health In Tech	MT

Communiqués

02/12	Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination	AQ
02/12	Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc	AQ
18/11	Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting	AQ
15/10/25	Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma	AQ
19/09/25	Sonnet to Present at the MedInvest Biotech & Pharma Conference	AQ
12/08/25	Sonnet Releases Virtual Investor What This Means Segment	AQ
11/08/25	Sonnet Releases Virtual Investor "What This Means" Segment	AQ
04/08/25	Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer	AQ
14/07/25	Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy	AQ
01/05/25	Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit	AQ
16/04/25	Sonnet Releases Virtual Investor "What This Means" Segment	AQ
07/04/25	Sonnet's SON-1010 demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose	AQ
04/04/25	Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose	AQ
01/04/25	Sonnet Announces Release of Corporate Update Video	AQ
01/04/25	Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.	AQ
26/03/25	Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas	AQ
19/03/25	Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein	AQ
11/03/25	Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference	AQ
26/02/25	Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors	AQ
19/02/25	Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates	AQ
18/02/25	Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference	AQ
13/02/25	Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer	AQ
13/02/25	Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update	AQ
29/01/25	Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB Platform Technology	AQ
28/01/25	Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology	AQ